My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Resolution 2024-069
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
Resolution 2024-069
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
5/22/2024 9:25:50 AM
Creation date
5/22/2024 9:24:53 AM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Fully Executed Version
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
130
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
Using speakers, key opinion leaders, thought leaders, lecturers, and/or <br />speaking events for Promotion of Opioids or Opioid Products; <br />Sponsoring, or otherwise providing financial support or In-Kind Support to <br />medical education programs for Promotion of Opioids or Opioid Products; <br />Creating, sponsoring, operating, controlling, or otherwise providing financial <br />support or In-Kind Support to any website, network, andlot social or other <br />media account for the Promotion of Opioids or Opioid Products; <br />Creating, sponsoring, distributing, or otherwise providing financial support or <br />In-Kind Support for materials Promoting Opioids or Opioid Products, <br />including but not limited to brochures, newsletters, pamphlets, journals, <br />books, and guides; <br />Creating, sponsoring, or othetwise providing financial support or In-Kind <br />Support for advertisements that Promote Opioids or Opioid Products, <br />including but not limited to internet advertisements or similar content, and <br />providing hyperlinks or otherwise directing internet traffic to advertisements; <br />and <br />Engaging in internet search engine optimization or other techniques designed <br />to Promote Opioids or Opioid Products by improving rankings or making <br />content appear among the top results in an internet search or otherwise be <br />more visible or more accessible to the public on the internet. <br />2. Notwithstanding subsection C.1 directly above, Janssen may: <br />a Maintain a corporate website; <br />Maintain a website for any Opioid Product that contains principally the <br />following content: the FDA-approved package insert, medication guide, and <br />labeling, and a statement directing patients or caregivers to speak with a <br />licensed Health Care Provider; <br />Provide information or support the provision of information as expressly <br />required by law or any state or federal government agency with jurisdiction <br />in Washington; <br />Provide the following by mail, electronic mail, on or through Janssen's <br />corporate or product websites or through other electronic or digital methods: <br />FDA-approved package insert, medication guide, approved labeling for <br />Opioid Products, or other prescribing information for Opioid Products that <br />are published by a state or federal government agency with jurisdiction in <br />Washington; <br />Provide scientific and/or medical information in response to an unsolicited <br />request by a Health Care Provider consistent with the standards set forth in <br />c-3 <br />b <br />c. <br />d. <br />e. <br />f. <br />o <br />b. <br />c <br />d. <br />e
The URL can be used to link to this page
Your browser does not support the video tag.